Capsovision, INC

CapsoVision Inc. announced the appointment of Dr. David S. Shields to its Board of Directors, effective July 1, 2026, succeeding Dr. Joanne Imperial who will continue as a consultant.

CapsoVision, Inc. stockholders re-elected three Class I Directors and ratified the appointment of Baker Tilly US, LLP as the independent auditor for fiscal year 2026.

CapsoVision announced its first quarter 2026 financial results, reporting stable revenue of $2.8 million, while highlighting progress on its AI-assisted reading feature and pipeline development.

CapsoVision announced a $14 million private placement, preliminary Q4 and full-year 2025 financial results, and updates on its CapsoCam Colon and pancreatic cancer detection programs.

CapsoVision, Inc. amended its development agreement with Canon Inc., increasing the total fee by $1 million for enhanced CMOS image sensor features.

CapsoVision, a medical technology company, announced the submission of its AI-assisted module for CapsoCam Plus to the FDA for 510(k) clearance, aiming to enhance diagnostic capabilities and reduce clinician review time.

CapsoVision, Inc. reported flat revenue for the first quarter of 2026 compared to the prior year, with a significant increase in research and development expenses.

CapsoVision reports increased Q3 2025 revenue driven by CapsoCam Plus sales, but faces substantial doubt about its going concern ability due to continued net losses and negative cash flows.

CapsoVision reports increased Q2 revenue driven by CapsoCam Plus sales, but net losses widened amid significant R&D and administrative costs, with IPO proceeds providing a liquidity boost.

CapsoVision reported increased revenue but widening net losses and a going concern warning, signaling significant financial and operational challenges despite product development efforts.

Eliyahou Harari, a 10% owner of CapsoVision, Inc, purchased 61,068 shares of common stock on July 17, 2026 for $6.73 per share.

Eliyahou Harari, a Director and 10% owner of CapsoVision, Inc., acquired 81,300 shares of common stock on July 8, 2026, for $6.09 per share.

Eliyahou Harari, a Director at CapsoVision, Inc., acquired 13,850 shares of common stock on June 26, 2026, for $7.35 per share.

Director Joanne Imperial of CapsoVision, Inc. reported the acquisition of 2,022 shares of common stock following the vesting of Restricted Stock Units.

Joanne Imperial, a Director at CapsoVision, Inc., reported a sale of 1,200 shares of common stock on June 8, 2026.

CapsoVision, Inc. reports that Director Tsai Chen Lung acquired 2,022 shares of common stock through the vesting of Restricted Stock Units.

CapsoVision, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, to be conducted virtually, with key agenda items including the re-election of Class I directors and ratification of its independent auditor.

CapsoVision, Inc. has filed a registration statement for the resale of 2,867,089 shares of common stock issued in a March 2026 private placement.

CapsoVision, Inc., a medical technology company specializing in capsule endoscopy, is launching an initial public offering of 5,250,000 shares at an anticipated price range of $5.00 to $5.50 per share, aiming to raise approximately $22.83 million in net proceeds to fund R&D and general corporate purposes, despite a history of net losses and substantial doubt about its ability to continue as a going concern.

CapsoVision, Inc., a medical technology company specializing in capsule endoscopy, filed an S-1/A registration statement for its initial public offering of 5,250,000 shares at an anticipated price range of $5.00 to $5.50 per share, aiming to raise approximately $22.83 million in net proceeds to fund R&D, repay a loan, and support general corporate purposes, despite a history of significant net losses and an auditor's going concern warning.

CapsoVision, Inc., a medical technology company specializing in capsule endoscopy, is seeking to raise approximately $22.83 million in its initial public offering to fund product development and commercial expansion, despite a history of net losses and auditor-raised substantial doubt about its ability to continue as a going concern.

CapsoVision, a medical technology company specializing in gastrointestinal diagnostics, has filed an S-1 registration statement for an initial public offering to support its growth strategies, including obtaining FDA clearance for its CapsoCam Colon capsule.

Eliyahou Harari and associated family trusts have filed a Schedule 13G reporting a 10.2% beneficial ownership stake in CapsoVision, Inc.

Shen Ching Hang and Star One Global Capital Limited have updated their filings to reflect a combined beneficial ownership of 12.8% in CapsoVision, Inc.

Several entities and individuals have filed an amendment to their Schedule 13G, reporting 0% beneficial ownership of CapsoVision, Inc. common stock as of March 31, 2026.

Shen Ching Hang has reported beneficial ownership of 8.5% of CapsoVision, Inc.'s common stock, totaling 3,991,607 shares.

Kioxia Corporation and its parent, Kioxia Holdings Corporation, have disclosed a beneficial ownership of 7.4% of CapsoVision, Inc.'s common stock.

A group of entities and individuals, including CID Greater China Venture Capital Fund III, L.P., has disclosed a 6.7% beneficial ownership stake in CapsoVision, Inc.